- Home
- PSNL vs ESPR Comparison
PSNL vs ESPR Comparison
Compare PSNL & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | ESPR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 898.5M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PSNL | ESPR |
|---|---|---|
| Price | $9.19 | $4.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $10.71 | $6.86 |
| AVG Volume (30 Days) | 1.4M | ★ 6.5M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $69,103,000.00 | ★ $303,802,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $2.83 | $0.69 |
| 52 Week High | $11.40 | $4.13 |
Technical Indicators
Market Signals| Indicator | PSNL | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.56 | 68.23 |
| Support Level | $9.34 | $3.72 |
| Resistance Level | $9.85 | $4.00 |
| Average True Range (ATR) | 0.78 | 0.25 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 31.13 | 96.17 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.